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Abstract
Introduction: The aim of the study was to determine whether Olf1/EBF associated zinc finger protein (OAZ), a
transcription factor encoded by a positional systemic lupus erythematosus (SLE) candidate gene, plays a functional
role in the pathogenesis in SLE.
Methods: Gene expression levels in peripheral blood cells (PBLs) measured using quantitative real-time polymerase
chain reaction (qPCR) were assessed for association with disease activity and the presence of specific
autoantibodies. Peripheral blood mononuclear cells (PBMCs) were incubated with specific siRNAs for three days,
then cells were harvested for measuring mRNA levels using qPCR, and supernatants for levels of total
immunoglobulin (Ig)G and IgM as well as secreted cytokines, chemokine and antinuclear antibodies (ANA) using
ELISA. Indirect immunofluorescence was also applied for ANA detection.
Results: OAZ gene expressions in PBLs from 40 ANA-positive SLE patients were significantly increased than
t h o s ef r o m3 0n o r m a lc o n t r o l s( P < 0.0001) and 18 patients with rheumatoid arthritis (P < 0.01). In SLE patients,
OAZ transcripts were positively correlated with SLE disease activity index (SLEDAI) score (r = 0.72, P < 0.0001)
and higher in those positive for anti-dsDNA or anti-Sm antibodies (both P < 0.05). Co-culturing with OAZ siRNAs
reduced mRNA levels of OAZ by 74.6 ± 6.4% as compared to those co-cultured with non-targeting siRNA and
OAZ silencing resulted in reduced total IgG, ANA, interferon (IFN)-g, interleukin (IL)-10, IL-12 and IL-21, but
elevated CCL2 levels in culture supernatants (P < 0.05). The declined ANA levels correlated with inhibited OAZ
expression (r = 0.88, P = 0.05), reduced IL-21 levels (r = 0.99, P < 0.01), and elevated chemokine (C-C motif)
ligand 2 levels (r = -0.98, P < 0.01). Expressions of ID1-3 were significantly down-regulated by 68.7%, 70.2% and
67.7% respectively after OAZ silence, while ID3 was also highly expressed in SLE PBLs (P < 0.0001) and
associated with disease activity (r = 0.76, P < 0.0001) as well as anti-dsDNA or anti-Sm antibodies (both
P < 0.05).
Conclusions: Elevated expression of OAZ transcripts in SLE PBLs were strongly correlated with disease activity.
Suppression of OAZ expression inhibited downstream ID levels, and secretion of ANA and IL-21, implicating a role
of OAZ pathway in the pathogenesis of SLE.
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Systemic lupus erythematosus (SLE) is a prototype auto-
immune disease with relatively strong genetic compo-
nents that genome wide linkage scans performed in the
past decade have identified chromosome 16p12.3 to
q12.2 to be the second-strongest locus linked to SLE
after HLA (6p22.3 to 6p21.1) [1-8]. A positional candi-
date gene, ITGAM located at 16p11.2, has been recently
identified and validated as a lupus susceptibility gene by
different groups [9-11]. However, fine mapping experi-
ments of the chromosome 16p locus have shown multi-
ple association signals clustering in several regions
[8,12], suggesting more than one gene may be involved
in the increased risk of SLE.
We have previously shown overall skewing of the
transmission of D16S517 (a microsatellite marker) alleles
and preferential transmission of one of its alleles from
heterozygous parents to offspring affected with SLE of
Chinese descent [13,14]. D16S517 is located within
intron 5 of a gene named Olf1/EBF associated zinc fin-
ger protein (OAZ, also known as zinc finger protein
423; ZNF423) in 16q12. Genotyping of five SNPs within
intron 4 and intron 5 of OAZ reveals preferential trans-
mission of haplotypes containing SNPs and/or the SLE-
associated D16S517 allele [14], suggesting OAZ may be
a positional candidate gene within the 16q interval.
Currently there is no evidence indicating OAZ in the
pathogenesis of SLE. OAZ is a transcriptional factor
that binds to DNA through its zinc fingers, which acts
as a bone morphogenetic protein (BMP) induced co-reg-
ulator of the Smad1 to Smad4 complex [15]. Through
model biology study, OAZ is found to be necessary in
BMP-4 induced gene activation [16]. Among the various
genes activated via BMP signaling, ID (inhibitor of dif-
ferentiation or inhibitor of DNA binding) proteins
involved in the regulation of cell differentiation and pro-
liferation may be the most important targets [17]. Four
ID proteins (ID1 to 4) have been identified in mammals,
in which ID3 is required for normal B cell functions
[18]. Thus, it is plausible that OAZ may act through
these IDs to regulate immune responses.
The presence of antinuclear antibodies (ANA), found
in 95% of the patients, is the most prevalent feature of
SLE that may play a pivotal role in the disease patho-
genesis. These antibodies bind to a variety of macromo-
lecules, including DNA, RNA and proteins, and some of
them, notably anti-dsDNA and anti-Sm, are specific for
the disease. Both the B-cell and T-cell compartments
exhibit functional abnormalities that could lead to the
autoantibody production in SLE [19]. Here we showed
that OAZ expression levels were elevated in patients
affected with SLE but not RA, correlated with disease
activity and associated with positivity for anti-dsDNA
and anti-RNA binding protein (anti-RBP) antibodies. In
addition, silencing OAZ expression correlated with
decreased production of ANA, IL-21, but elevated
CCL2. These findings support a role of OAZ in the
pathogenesis of SLE.
Materials and methods
Patients and controls
Study protocol was reviewed and approved by the Ethics
Committee of the Affiliated Drum Tower Hospital of
Nanjing University Medical School where all subjects
were recruited, excluding those with a current infection.
All patients and healthy volunteers provided written
informed consents to participate in the study. Enroll-
ment criteria for SLE patients were 1) fulfillment of the
1997 revised criteria of the American College of Rheu-
matology [20], and 2) with positive serum ANA (a titer
>1:100 dilution) at the study entry. Healthy volunteers
were recruited as normal controls with an effort to
match age and gender of SLE patients. Rheumatoid
arthritis (RA) patients who meet the 1987 American
College of Rheumatology classification criteria [21] were
recruited as disease controls. In total 40 SLE patients,
30 normal controls and 18 RA patients were enrolled
for measuring the gene expressions in peripheral blood
cells (Table 1).
At the beginning of the study, each SLE patient was
assessed for the presence of ANA and IgG antibodies to
anti-dsDNA and anti-extractable nuclear antigen using
reagents from Euroimmun AG (Lübeck, Germany) and
disease activity at the time of blood drawn was assessed by
their rheumatologists and verified by two of the authors
(RL and BH) using the SLE disease activity index (SLEDAI)
[22]. Among the 40 patients having their gene expressions
measured in peripheral blood, 38 were treated with steroids
(an average dose of 34.6 ± 2.6 mg per day of methylpredni-
solone (from 6 mg to 80 mg according to their disease
activity)), 18 were taking hydrochloroquine, 5 were on
cellcept or cyclosporin and 8 were on non-steroidal anti-
inflammatory drug at the time of blood draw.
Sample collection and RNA processing
A 2 to 3 ml sample of blood was collected in BD Vacutai-
ner spray-coated K2EDTA Tubes (BD Biosciences, San
Jose, CA, USA) and total RNA from whole cells was
extracted immediately using Trizol (Invitrogen, Carlsbad,
CA, USA). A 1 to 2 μg aliquot of total RNA was reverse
transcribed into complementary DNA (cDNA) using
Superscript II reverse transcriptase (Invitrogen, USA). All
RNA and cDNA samples were stored at -70°C before use.
Gene expression measuring
Primers were designed using the Primer Express 2.0
Software (Applied Biosystems, Foster City, CA, USA)
according to the total mRNA sequences of OAZ
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ID3 (NM_002167) and ID4 (NM_001546). Human ribo-
somal protein, large, P0 (RPLP0) was used as the house-
keeping gene to normalize cellular RNA amounts. All
the primers were synthesized by Takara Corp (Shanghai,
China) and the sequences were shown in Table 2.
Experiments were performed in triplicate for each
sample in 96-well plates using SYBR Green I Dye in the
Applied Biosystems 7500 real-time PCR system. Reac-
tions were performed in a 20 μl reaction volume and
cycling times and temperatures were as follows: initial
denaturation was carried out for 10 seconds at 95°C, fol-
lowed by 45 cycles of denaturation at 95°C for 5 seconds
and combined primer annealing/extension at 60°C for
34 seconds. Data were displayed using SDS software,
version 2.0 (Applied Biosystems, USA). The ΔCT value
was determined by subtracting the RPLP0 (the house
keeping gene) CT value from the target gene CT value.
Relative gene expressions were calculated as 2
-(ΔCT each-
ΔCT mean) where ΔCT each = ΔCT value of each sample,
ΔCT mean = mean ΔCT values of normal controls.
RNA Interference
Accell siRNA was a novel form of short-interfering RNA
that was absorbed directly by cells without the use of
conventional delivery methods such as transfection
reagents or viruses. Four pairs of siRNA sequences
targeting OAZ were designed and synthesized by Dhar-
macon (Accell SMARTpool siRNA A-012907 13-16,
Thermo Fisher Scientific, Waltham, MA, USA). SiRNA
with a non-targeting sequence was used as a negative
control, and siRNA targeting glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as a positive
control (Table 3).
Blood was drawn from five randomly selected female
SLE patients (40.40 ± 1.69 yrs old) and OAZ gene silen-
cing was performed according to the manufacturer’s
instructions (Dharmacon). Briefly, mononuclear cells
were collected by Ficoll-Hypaque discontinuous gradi-
ent, resuspended in siRNA buffer, distributed to 96-well
plate at 2 × 10
5 per well, and then divided into OAZ
silence group (OAZ sil, added with OAZ siRNA mixture
using SMARTpool technique), positive control group
(added with GAPDH siRNA), negative control group
(Neg ctl, added with non-targeting siRNA) and mock
group (only culture medium added). For each sample, 4
to 10 replications in each group were applied. Cells
were incubated at 37°C with 5% CO2 for 72 hour and
trypan blue exclusion test of cell viability was done by
counting 200 cells before and after cell culture. After
culturing, supernatants were collected and cells were
harvested, RNA was extracted and then reverse tran-
scribed to cDNA. Specific inhibition efficacy of OAZ,
ID1-4 and GAPDH was confirmed by qPCR.
Table 2 Primers for real-time PCR
Gene Forward Reverse
OAZ CTG CTC ACA GTG CCC TCA GAA G ACT GTG CGT GCT GGC TCA TC
ID1 GTA AAC GTG CTG CTC TAC GAC ATG A AGC TCC AAC TGA AGG TCC CTG A
ID2 TGT CAG CCT GCA TCA CCA GA CCA CAC AGT GCT TTG CTG TCA
ID3 TCA GCT TAG CCA GGT GGA AAT C GGC TGT CTG GAT GGG AAG GT
ID4 GAT CCT GCA GCA CGT TAT CGA CT AAT GCT GTC GCC CTG CTT G
RPLP0 GTT TCA TTG TGG GAG CAG ACA CAT GGT GTT CTT GCC CAT CA
PCR, polymerase chain reaction.
Table 1 Demographics of SLE patients, normal controls and disease controls*
SLE patients (n = 40) Normal controls (n = 30) Disease controls (n = 18)
+
Age, years 33.48 ± 2.11 (14 to 70) 29.23 ± 1.13 (19 to 42) 38.39 ± 2.02 (18 to 54)
Female gender 33 (82.5%) 24 (80.0%) 17 (94.1%)
Disease duration, years 5.91 ± 0.94 (0.08 to 20)
SLEDAI score 7.70 ± 0.90 (1 to 27)
Autoantibodies
Anti-dsDNA 15 (37.5%)
Anti-Sm 19 (47.5%)
Anti-SSA 18 (45.0%)
Anti-SSB 14 (35.0%)
Anti-U1RNP 9 (22.5%)
*Values are shown by mean ± SEM (range) or number (percentage). There were no significant differences between patients with systemic lupus erythematosus
(SLE) and normal controls or disease controls in terms of age and gender.
+Consisted of 18 patients with rheumatoid arthritis. SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
Feng et al. Arthritis Research & Therapy 2010, 12:R59
http://arthritis-research.com/content/12/2/R59
Page 3 of 12Immunoglobulin and antinuclear antibody detection
Total IgG and IgM levels were measured by commercial
ELISA kits (Westang Bio-Tech Co., Shanghai, China).
Cultured supernatants were diluted in 1:10 for IgG test
and undiluted for IgM test. ANA levels were detected
by ELISA and also indirect immunofluorescence accord-
ing to manufacturer’s instruction (Euroimmun, Lübeck,
Germany). An ANA value for each sample was calcu-
lated by OD sample/OD standard obtained from the ELISA
test. As for the immunofluorescence test, undiluted
samples were layered on HEp-2 cell spots and incubated
for 30 minutes. After washing, fluorescein-labeled anti-
human globulin was added to each spot and incubated
for another 30 minutes. Slides were then embedded and
read under the fluorescent microscope (Olympus;
Tokyo, Japan). The criterion for assigning intensity of
fluorescence was as follows: 4+ (very bright green), 3+
(bright green), 2 + (green), 1 + (faint green).
Cytokine and chemokine measurements
Interferon g (IFN-g), interleukin 4 (IL-4), IL-10, IL-12,
IL-21 and chemokine (C-C motif) ligand 2 (CCL2) levels
in supernatants obtained from the previous step were
measured by EIA kits (R & D Systems, Minneapolis,
MN, USA). For each cytokine, samples and diluted stan-
dards were added to pre-embedded plate and incubated
for two hours at 37°C. Then biotinylated anti-human
detection antibody was added to each well. The plate
was incubated for one hour at 37°C and developed with
the addition of Streptavidin-HRP and tetramethylbenzi-
dine as a substrate. The optical density for each well
was documented with a microplate reader (Tecan Sun-
rise, Männedorf, Switzerland) set to 450 nm and levels
of cytokines and chemokine (pg/ml) were calculated
according to their standard curves.
Statistical analysis
Results are presented as means ± SEM. Because gene
expressions were extremely altered in certain patients,
those levels were transformed to log10 values for analy-
sis. To observe the changes of gene expressions, cyto-
kine/chemokine levels and ANA values due to OAZ
silence, an excitation-inhibition ratio (EIR) for each
sample was calculated according to the formula:
EIR 
ValueOAZsil
ValueNegctr . For comparing the results between
two groups, Student’s t-test was conducted if the variance
was normally distributed, whereas the Mann-Whitney
U test was used if the variance was not normally distribu-
ted. Correlation between groups was evaluated using the
Pearson rank test. Data were analyzed using the Prism
3.0 program (GraphPad, La Jolla, CA, USA), and P <0 . 0 5
was considered significant.
Results
OAZ highly expressed in SLE patients and correlated
with disease activity
To explore whether OAZ was differentially expressed in
SLE, mRNA levels relative to a house keeping gene were
measured by qPCR using peripheral blood cells from 40
SLE patients, 30 matched normal controls and 18 RA
patients, and then transformed to log10 values. As shown
in Figure 1a, OAZ gene were highly expressed in periph-
eral blood samples from SLE patients as compared to
those from normal controls (0.79 ± 0.13 vs 0.001 ± 0.109,
P < 0.0001) and RA patients (0.79 ± 0.13 vs -0.04 ± 0.22,
P < 0.01), while there was no difference between those
from normal controls and RA patients (P >0 . 0 5 ) .T h e
expression data of OAZ in SLE patients were compared
with varying levels of disease activity as assessed by the
SLEDAI score at the time blood was obtained. A positive
correlation between OAZ values and SLEDAI scores was
observed (Pearson r = 0.72, P < 0.0001) (Figure 1b).
OAZ associated with autoantibody production in SLE
patients
Since the production of antinuclear autoantibodies is the
most ubiquitous feature in SLE, SLE predisposing fac-
tors should impact on ANA production [23]. Within
our 40 patients, all had a positive ANA (titers >1:100) at
the time of blood draw, while 15 had concurrent IgG
anti-dsDNA, 19 had anti-Sm, 18 had anti-SSA, 14 had
a n t i - S S Ba n d9h a da n t i - U 1R N P .W ef o u n dO A Z
expressions were higher in patients with positive anti-
dsDNA antibodies as well as in those with positive anti-
Sm antibodies (both P < 0.05, Figure 1c). However,
there were no associations between OAZ expression and
anti-SSA, SSB or U1RNP antibodies (data not shown).
Diminished ANA production after OAZ silence
To assess whether OAZ expression might regulate auto-
antibody production in vitro, mRNA expression in per-
ipheral blood mononuclear cells from SLE patients were
Table 3 Accell siRNA sequences
Gene Sense Antisense
OAZ GUA AUG AAU AUA AUC
GGU U
AAC CGA UUA UAU UCA
UUA C
OAZ GCA UCA ACC ACG AGU
GUA A
UUA CAC UCG UGG UUG
AUG C
OAZ GGA GGA UGA AUC AAU
UUA C
GUA AAU UGA UUC AUC
CUC C
OAZ CCU UCA UGU AUU AUA
UUG A
UCA AUA UAA UAC AUG
AAG G
Nt UUC UCC GAA CGU GUC
ACG U
ACG UGA CAC GUU CGG
AGA A
GAPDH GUA UGA CAA CAG CCU
CAA G
CUU GAG GCU GUU GUC
AUA C
Nt, non-targeting siRNA
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GAPDH as a specificity control, or siRNA with a non-tar-
geting sequence as a negative control. The percentages of
viable cells were 97.6 ± 1.5% before cell culture and 94.7
± 1.3% after the culture and there were no differences in
viability among groups. Compared to those from the
negative control group (using non-targeting siRNA),
OAZ expressions were significantly decreased only in
culture cells treated with siRNA specific for OAZ with a
74.6 ± 6.4% reduction of expression level (Figure 2a).
Mean expression of GAPDH was not inhibited by OAZ
siRNA, and was decreased by 84.9 ± 4.7% by GAPDH
siRNA in the positive control group (Figure 2b).
ANA were present in all studied SLE patients, making
ANA the most useful test to measure the change of
autoantibodies after OAZ knockdown. Because most
SLE patients did not have positive anti-dsDNA antibody
and anti-Sm antibody in their serum, we measured
ANA in culture supernatants as an alternative. As
shown in Figure 2c, ANA value was 2.30 ± 0.20 in the
negative control group and 0.13 ± 0.03 in the OAZ
knockdown group measured by ELISA (P < 0.01). There
was no difference in ANA value between negative con-
trol group and GAPDH knockdown group (P > 0.05).
Consistent with ELISA results, intensity of ANA fluores-
cence was decreased from 2 to approximately 3+ in the
Figure 1 OAZ highly expressed in SLE patients and associated with disease activity as well as anti-dsDNA and anti-Sm antibodies. a.
Elevated OAZ expressions in peripheral blood cells from SLE patients. Each symbol represents an individual sample and horizontal lines shows
mean values. The log10 values of OAZ expression levels were 0.79 ± 0.13 in SLE patients, 0.001 ± 0.109 in normal controls and -0.04 ± 0.22 in RA
patients. b. OAZ expression correlated with SLE disease activity index (SLEDAI). According to Pearson’s correlation test, the log10 values of OAZ
expression levels in peripheral blood cells from 40 SLE patients were significantly correlated with SLEDAI scores (r = 0.72, P < 0.0001). c. OAZ
expression associated with anti-dsDNA and anti-Sm antibodies. Each symbol represents an individual sample and horizontal lines showed mean
values. Patients were divided into two groups according to their anti-dsDNA or anti-Sm antibody detection results at the time of blood drawn.
Those with positive anti-dsDNA antibody or anti-Sm antibody had a higher expression of OAZ in peripheral blood than those without (both
P < 0.05).
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Page 5 of 12Figure 2 Blockade of ANA production after OAZ silencing in vitro. a. OAZ expression decreased after the silence of OAZ. The highest
expression level was set to be 1 (100%) and expression data in Mock group (mock), OAZ silence group (OAZ sil), GAPDH silence group (GAPDH
sil) and negative control group (NC) were shown as mean values ± SEM. A significant decline of mRNA expression was found in the OAZ silence
group comparing to that in the negative control group (P < 0.05). b. GAPDH expression dramatically decreased after the silence of GAPDH.
Values were shown as mean ± SEM. A significant decline of mRNA expression was found in the GAPDH silence group comparing to that in the
negative control group (P < 0.05). c. Decreased ANA level after OAZ silencing. ELISA was preformed to measure the production of ANA and data
were shown as mean OD values ± SEM. A dramatically decline of ANA production was found in the OAZ silence group as compared to
negative control group and GAPDH silence group (** P < 0.01). d. Decreased intensity of ANA fluorescence after OAZ silencing. Representative
photomicrographs of ANA fluorescence in negative control group, OAZ silence group and GAPDH silence group were shown. After OAZ silence,
only weak fluorescence was observed. e. Association of OAZ expression and ANA level. The excitation-inhibition ratio (EIR) of OAZ expression
was positively correlated with EIR of ANA value after gene silencing (Pearson r = 0.88, P = 0.05).
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using indirect immunofluorescence (Figure 2d). There
was a positive correlation between the EIR of OAZ
expression and ANA value (r = 0.88, P =0 . 0 5 )( F i g u r e
2e), suggesting that OAZ might play a role in ANA
production.
To further confirm a relationship between OAZ
expression and antibody production, total IgG and IgM
in culture supernatants were measured. IgG levels were
significantly decreased in the OAZ knockdown group as
compared to those in the negative control group (26.8 ±
3.7 ug/ml vs 44.3 ± 6.4 ug/ml, P < 0.05), while there
was no difference in IgM levels between the two groups
(4.13 ± 0.56 ug/ml vs 2.82 ± 0.36 ug/ml, P = 0.09).
Alteration of cytokine and chemokine levels after OAZ
silence
Production of IgG autoantibodies requires T cell help,
and there are several subpopulations of effector CD4
+ T
lymphocytes (Th cells) based on the cytokines they pro-
duced. To assess whether OAZ was linked to the cyto-
kine disturbance that was a prominent phenomenon in
SLE, we tested the secretion levels of two Th1 cytokines
(IFN-g and IL-12), two Th2 cytokines (IL-4 and IL-10)
and one newly discovered Th17-related cytokine (IL-21).
As shown in Figure 3a, four of the five cytokines mea-
sured were significantly down-regulated after OAZ silen-
cing compared to those in the negative control group.
The levels of IFN-g, IL-10, IL-12 and IL-21 were 37.8 ±
2.6 pg/ml, 175.7 ± 42.0 pg/ml, 160.8 ± 28.1 pg/ml and
69.0 ± 5.5 pg/ml in the group treated with siRNA to
OAZ, while the levels were 21.7 ± 1.5 pg/ml, 52.4 ± 8.9
pg/ml, 30.0 ± 9.3 pg/ml and 28.1 ± 3.6 pg/ml in the
negative control group (P <0 . 0 1 ,P <0 . 0 1 ,P <0 . 0 5a n d
P < 0.01 respectively). There was no difference in IL-4
level between the two groups. CCL2, a chemokine that
has been implicated as a biomarker for lupus nephritis
[24], was significantly increased in the OAZ silenced
group compared to those in the negative control group
(298.3 ± 65.3 vs 531.5 ± 46.5, P < 0.05) (Figure 3a).
To identify the relationship between OAZ expression
and specific cytokines and/or chemokine, EIR was calcu-
lated as described before. There was a positive trend of
correlation between the EIR of OAZ expression and the
EIR of IL-21 level (r = 0.83, P = 0.08, Figure 3b), sug-
gesting the more decreased levels of OAZ, the lower
levels of IL-21. The EIR of OAZ expression was nega-
tively correlated with the EIR of CCL2 level (r = -0.89, P
< 0.05, Figure 3c), indicating a strong negative correla-
tion between OAZ transcripts and the secreted levels of
CCL2 in cultures of peripheral blood cells from SLE
patients.
Strikingly, there was a perfect positive correlation
between EIR of IL-21 levels and EIR of ANA value, and
a negative correlation between EIR of CCL2 levels and
EIR of ANA value (r = 0.99 and r = -0.98, both P <
0.01) (Figure 3d, e), providing evidence that these two
factors might be important in the production of ANA.
ID3 gene participated in OAZ pathway in SLE
Since ID expression might be regulated by OAZ, expres-
sions of all the four ID genes were measured after OAZ
knockdown. ID1 to 3, but not ID4, were significantly
down-regulated with an average decline of 68.7%, 70.2%
and 67.7%, respectively, as compared to those of nega-
tive control (Figure 4a), supporting that expression of
these genes in SLE patients might be regulated by the
pathway involving OAZ.
Among the four IDs, ID3 that had putative immuno-
f u n c t i o n s[ 2 5 ]w a ss e l e c t e da sar e p r e s e n t a t i v ef o rin
vivo studies. To assess whether ID3 expressions were
related to the disease status, qPCR was applied using
peripheral blood cells from 40 SLE patients and 20 nor-
mal controls. Our data showed that ID3 was highly
expressed in SLE patients compared to that in normal
controls (0.75 ± 0.09 vs 0 ± 0.11, P < 0.0001) and there
was a positive correlation between ID3 expression level
and SLEDAI score (r = 0.76, P < 0.0001) (Figure 4b, c).
Meanwhile, a correlation between OAZ and ID3 expres-
sion levels was observed (r = 0.55, P = 0.0002). ID3
expressions were also elevated in those with positive
anti-dsDNA or anti-Sm antibodies (Figure 4d), indicat-
ing that ID3 could play a role in the regulation of OAZ
driven ANA production.
Abnormal activation of the type I interferon pathway
presents in most SLE patients particularly in those
expressing anti-RBP antibodies [26]. To address whether
siRNA for OAZ might non-specifically inactivate the
type I interferon pathway, the expression level of LY6E,
a type I interferon inducible gene [27], was measured
after OAZ knockdown. No significant alteration of LY6E
expression was observed among groups treated with
non-targeting GAPDH- or OAZ- targeting SiRNA (data
not shown).
Discussion
T oo u rk n o w l e d g e ,t h i si st h ef i r s tr e p o r tt oi m p l i c a t ea
functional role of OAZ, a novel positional lupus candi-
date gene, in the pathogenesis of SLE. Dysregulation of
OAZ expression modulated the ANA production of SLE
patients. Our studies showed that OAZ mRNA levels in
peripheral blood cells were elevated in SLE patients as
compared to those in either normal or disease controls
(RA patients). Transcript levels of OAZ were highly cor-
related with disease activity (r = 0.72, P < 0.0001) as
well as associated with the presence of autoantibodies to
dsDNA or Sm (Figure 1). OAZ expressions were nega-
tively correlated with methylprednisolone doses (data
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greater elevation of OAZ expression in those patients
with high SLEDAI scores because they were treated with
high dose of steroids. When OAZ expression in periph-
eral blood mononuclear cells was silenced in vitro,
mRNA levels of OAZ and ID1-3 were concomitantly
decreased, together with a reduction of IFN-g,I L - 1 0 ,I L -
12 and IL-21 levels, an elevation of CCL2 level, and
decreased levels of total IgG and ANA (Figures 2 and 3).
The extent of decreased ANA level was correlated with
the inhibition of OAZ expression, the reduction of IL-21
level and the elevation of CCL2 level. Interestingly, ID3, a
gene that was down-regulated after OAZ silence, was
also highly expressed in SLE patients and associated with
disease activity as well as the presence of anti-dsDNA or
anti-Sm autoantibodies (Figure 4).
OAZ is present in cell nucleus and acts as a DNA-
binding partner of BMP-Activated Smads [15].
Figure 3 Alteration of cytokine and chemokine levels after OAZ silencing. a. IFN-g, IL-10, IL-12 and IL-21 levels were significantly decreased
in culture supernatants of OAZ silence group (silence) as compared to those of negative control group (control), while IL-4 levels remained
unchanged and CCL2 levels were increased in culture supernatants of silence group. Values were shown as means ± SEM (** P < 0.01, * P <
0.05). b, c. The relationship between OAZ expression and IL-21 as well as CCL2. There was a tendency for the excitation-inhibition ratio (EIR) of
OAZ expression to be positively correlated with EIR of IL-21 level (Pearson r = 0.83, P = 0.08), while the EIR of OAZ expression was negatively
correlated with EIR of CCL2 level (Pearson r = -0.89, P < 0.05). d, e. Association of IL-21, CCL2 and ANA level. EIR of IL-21 level was positively
correlated with EIR of ANA value (Pearson r = 0.99, P < 0.01), while EIR of the CCL2 level was negatively correlated with EIR of ANA value
(Pearson r = -0.98, P < 0.01).
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Page 8 of 12Figure 4 ID3 associated with disease activity as well as anti-dsDNA and anti-Sm antibodies. a. Expressions of ID genes decreased after
OAZ silencing in vitro. Cells collected from silence study were applied for the detection of ID1 to 4 expressions using qPCR. The EIR was
obtained for each subject and the inhibition efficacy was then calculated as (1-EIR) ×100%. After OAZ silencing, expression levels of ID1, ID2, ID3
and ID4 were reduced by 68.7%, 70.2%, 67.7% and 43.3%, respectively. b. Elevated ID3 expressions in peripheral blood cells from SLE patients.
Each symbol represents an individual sample and horizontal lines show median values. The relative expression levels of ID3 were 0.75 ± 0.09 in
SLE patients and 0 ± 0.11 in normal controls (P < 0.0001). c. ID3 expression correlated with SLE disease activity. According to Pearson’s
correlation test, log 10 values of ID3 expression levels were significantly correlated with SLEDAI scores (r = 0.76, P < 0.0001). d. ID3 expression
associated with anti-dsDNA antibody and anti-Sm antibody. Each symbol represents an individual sample. Those with positive anti-dsDNA
antibody had higher expression of ID3 in peripheral blood than those without (P < 0.05), as did those with positive anti-Sm antibody (P < 0.05).
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Page 9 of 12According to our results, mRNA expression of OAZ is
very low in peripheral blood cells (approximately 0.002%
of the expression level of the house-keeping gene), mak-
ing it difficult to be detected in the protein level. To
ensure a specific amplification of this gene, primers have
been blasted after the design a t i o n[ 2 8 ] .B e s i d e s ,o n l y
OAZ but not EHZF, an OAZ homology gene that highly
expressed in primitive human hematopoietic cells [29],
showed differential expression in bone marrow cells
between SLE patients and healthy donors in our preli-
minary study. The Accell siRNA delivery method, which
has recently been widely used to silence genes in many
cell types including those difficult-to-transfect immune
cells [30-32], provides us a highly efficient way to study
genes with low expressions but important functions.
In this paper, OAZ was found to be associated with
autoantibody production in vivo and in vitro, suggesting
that highly expressed OAZ in SLE patients might pro-
mote differentiation of B lymphocytes to antibody-
secreting cells. Support evidence for this hypothesis
includes that 1) overexpression of OAZ in the neuro-
blastoma cells leads to enhanced differentiation [33],
and 2) suppression of OAZ expression reduces cell
growth and contributes to the blast crisis stage in
chronic myelogenous leukemia mouse model as the
result of the differentiation block [34]. However, it is
not clear how OAZ mediates its role in cell differentia-
tion at present. As one of the largest members of the
Kruppel-like zinc finger protein family, OAZ provides
specificity in BMP signaling while ID genes are thought
to be important targets of BMP signaling [15,35]. Based
on the study of osteoblast differentiation of mesenchy-
mal stem cells, both RNA interference-mediated knock-
down and constitutive overexpression of Id genes are
associated with diminished cell differentiation, implicat-
ing that Id proteins could play a dual role in BMP-
mediated differentiation [36].
Among the four ID proteins, ID3 is known to have
important functions in the immune system, although its
specific role is yet to be delineated. Young ID3-deficient
mice (6 to 12 weeks old) have defective immune
responses displaying as a B-cell defect in the proliferation
and attenuated antibody production [25]. Meanwhile, the
production of IgG2a (a Th1 response immunoglobulin) is
impaired along with a decreased expression of IFN-g
when stimulated with anti-CD3 in these mice. When
E2A, an ID3 antagonist gene, was knocked down, mice
frequently developed ANA and proteinuria at age eight
months or older [37]. Thus a sustained high expression
of ID3 might trigger abnormal immunity in SLE patients,
facilitating the production of autoantibodies. To support
this notion, our current data have shown a good correla-
tion between ID3 and OAZ expressions and an associa-
tion of ID3 expression with both anti-dsDNA and
anti-Sm antibodies. Besides ID pathway, OAZ has been
shown to be a component of retinoic acid signaling, and
plays a key role in retinoic acid-induced differentiation
through the regulation of retinoic acid receptors [33]. In
addition, OAZ may act as a corepressor of EBF (early B
cell factor) [38], and thus inhibit the transcription of a lot
B lineage genes including Pax-5 [39] and consequently
affect plasma cell differentiation [40,41]. It is reasonable
that these pathways could also be helpful in OAZ
induced B lymphocyte differentiation and antibody pro-
duction in SLE patients.
Studies have implicated that cytokines and chemo-
kines are involved in the differentiation of B lympho-
cytes into plasma cells [42,43]. The decreased level of
Th1cytokines (IFN-g and IL-12) in our case after OAZ
silence is similar to that found in ID3-deficient mice
[25], supporting a role of OAZ-ID3 pathway in this pro-
cess. IL-10 is a well-known mediator of human B cell
differentiation that has a powerful effect on the stimula-
tion of immunoglobulin secretion by B cells in SLE [44].
IL-21 has a critical role in terminal B cell differentiation
to plasma cells and has recently been identified as an
important component in the development of autoim-
mune disease [45-47]. Our in vitro results suggested
that OAZ could regulate IL-10 and IL-21 level in SLE.
The near perfect correlation between the extent of IL-21
and ANA suppression by OAZ knockdown suggested
that this cytokine could be a key mediator for OAZ
induced B cell differentiation and ANA production. In
addition to these cytokines, a chemokine, CCL2, has
been shown to suppress plasma cell immunoglobulin
production via STAT3 inactivation and PAX5 induction
[48]. Of note, the expression of CCL2 is effectively regu-
lated by BMP members [49]. In our experiment, CCL2
might work as a negative regulator of plasma cell differ-
entiation when upregulated via OAZ silence.
Conclusions
OAZ has been previously considered as a positional can-
didate gene for susceptibility to SLE. Our data provide
evidence for functional relevance of OAZ in SLE in the
production of antinuclear antibody, a hallmark of SLE,
along with the alterations of several cytokines and che-
mokine especially those involved in the regulation of
plasma cell function. As a complex network, BMP-
Smad-IDs, retinoic acid receptor and Olf-1/EBF path-
ways could participate in OAZ-driven ANA production.
Further studies are required for elucidating the molecu-
lar mechanisms of the OAZ gene in the development of
autoimmune diseases.
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